The pharmaceutical titan Novartis is engaged in a complex legal battle to prevent the release of generic versions of its cardiovascular medication, Entresto. This has resulted in a series of legal actions, including multidistrict litigations, cases filed in various circuit courts, and actions involving the federal government. As Novartis seeks to maintain its market exclusivity for this high-performing drug, the legal entanglements continue to unfold on multiple fronts.
For more details on the litigation strategy and how these legal proceedings are interconnected, access the comprehensive coverage by Law360 here.